Magpie trial (magnesium sulfate in pre-eclampsia)
A very large trial of 10,141 women with pre-eclampsia in 33 countries. Half were given magnesium sulphate and half a dummy treatment. Magnesium sulphate cut the risk of eclampsia, seizures in pre-eclampsia, by more than half. It did not clearly change the risk of the baby dying. Side-effects were reported more often with magnesium sulphate.
Also called Magpie · Magpie Trial
- Study
- In this atlas
Overview
- Design
- Multicentre randomised placebo-controlled trial. Analyses were by intention to treat. Follow-up was until discharge from hospital after delivery.
- Phase
- Not reported
- Enrolled
- 5,071 women allocated magnesium sulphate
- 5,070 women allocated placebo
- Sponsor
- Not recorded
- Funder
- Not recorded
- Registry
- Not reported
- Started
- Not reported
- Primary completion
- Not reported
- Completion
- Not reported
- Countries
- Not reported
- Care setting
- Not reported
- Registry status
- Not reported
Technical summary
Randomised placebo-controlled multicentre trial (2002; PMID 12057549). 5071 women were randomised to magnesium sulphate and 5070 to placebo; analyses were by intention to treat; follow-up data were available for 10 110 women. Primary outcomes were eclampsia and, for women randomised before delivery, death of the baby. No registry record is recorded here (the ISRCTN number is not printed in the PubMed record), so the study has no registry dates or status; the abstract does not name the countries or the sites. The trial publication is a single paper.
Arms
-
Magnesium sulphate
Intervention Magnesium sulfate to prevent and treat eclampsia
Magnesium sulphate for women with pre-eclampsia (dose and route are not given in the abstract).
-
Placebo
Intervention
Placebo.
Findings
No findings are published for this study.
Record details
- Record id
maternal:magpie-trial- Content hash
e95e6833e0ba0f8c9dccf36b9f95ec4fc9e5547041194ef0bc15c98aad94c997